Patents by Inventor Jeffrey A. Clanton

Jeffrey A. Clanton has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 5480631
    Abstract: Novel, substituted benzamides in radioiodinated form are useful in radiopharmaceutical compositions in nuclear medicine as imaging agents to detect, visualize, and analyze the distribution and function of the dopamine D2 receptor in the mammalian brain. These compounds have a specific combination of lipophilicity and dopamine D2 receptor affinity required to attain a required image contrast. The iodinated benzamides identified by the above discovery can be made by reacting a trialkyltin substituted benzamide with an acid in the presence of radioactive iodine which, in turn, is generated by in situ oxidation of an appropriate iodide nuclide salt.
    Type: Grant
    Filed: May 28, 1992
    Date of Patent: January 2, 1996
    Assignee: Vanderbilt University
    Inventors: Tomas De Paulis, Robert M. Kessler, Howard E. Smith, Aaron Janowski, Jeffrey A. Clanton
  • Patent number: 5154913
    Abstract: Novel, substituted benzamides in radioiodinated form are useful in radiopharmaceutical compositions in nuclear medicine as imaging agents to detect, visualize, and analyze the distribution and function of the dopamine D-2 receptor in the mammalian brain. The substituted benzamides and their racemic mixtures or their optically resolved enantiomers can be made by reacting a trialyltin substituted benzamide with an acid in the presence of radioactive iodine, generated by in situ oxidation of an appropriate iodide nuclide salt.
    Type: Grant
    Filed: May 28, 1991
    Date of Patent: October 13, 1992
    Assignee: Vanderbilt University
    Inventors: Tomas de Paulis, Robert M. Kessler, Howard E. Smith, Aaron Janowsky, Jeffrey A. Clanton
  • Patent number: 4615879
    Abstract: Contrast media compositions for nuclear magnetic resonance (NMR) imaging of the gastrointestinal system are provided for oral or rectal administration. The compositions comprise aqueous suspensions of particles of an NMR contrast agent, the particles being very finely-divided and providing in their outer surfaces a substantially water-insoluble paramagnetic compound. Suspending and/or wetting agents may be included to maintain the contrast agent particles in a dispersed, suspended condition for the oral or rectal administration. Buffering agents may also be included to maintain the pH of the suspension in a pH range protecting the insolubility of the paramagnetic compound.
    Type: Grant
    Filed: November 14, 1983
    Date of Patent: October 7, 1986
    Assignee: Vanderbilt University
    Inventors: Val M. Runge, Jeffrey A. Clanton